NCT04389801

Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

Status unknown Phase 4 Last updated 15 May 2020

What this trial tests

Phase 4 trial testing Desferal 500 MG Injection in Covid 19 in 200 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
30 September 2020

31 December 2020

Quick facts

Lead sponsor	Hesham Al-Inany
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	1 June 2020
Primary completion	30 September 2020
Estimated completion	31 December 2020

Drugs / interventions tested

• Desferal 500 MG Injection — full drug profile →

Conditions studied

• Covid 19 — all drugs for Covid 19 →

Sponsor

Hesham Al-Inany — full company profile →

Who can join

Eligibility, any sex, with Covid 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
   Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
2. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
   Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
3. Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
   Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6
4. The role of cell death in SARS-CoV-2 infection.
   Yuan C, Ma Z, Xie J, Li W, et al · · 2023 · cited 51× · PMID 37726282 · DOI 10.1038/s41392-023-01580-8
5. The Relationship Between Hepcidin-Mediated Iron Dysmetabolism and COVID-19 Severity: A Meta-Analysis.
   Peng D, Gao Y, Zhang L, Liu Z, et al · · 2022 · cited 16× · PMID 35558525 · DOI 10.3389/fpubh.2022.881412
6. The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death.
   Xie J, Yuan C, Yang S, Ma Z, et al · · 2024 · cited 14× · PMID 39516736 · DOI 10.1186/s11658-024-00659-6
7. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.
   Amini Pouya M, Afshani SM, Maghsoudi AS, Hassani S, et al · · 2020 · cited 10× · PMID 32734518 · DOI 10.1007/s40199-020-00359-4